| Autor: |
Alarcón, Graciela S, Parker, Ben, Clarke, Ann E, Sanchez-Guerrero, Jorge, Manzi, Susan, Gordon, Caroline, Rahman, Anisur, Sturfelt, Gunnar K, Urowitz, Murray B, Donn, Rachelle, Fortin, Paul R, Petri, Michelle, Ginzler, Ellen M, Isenberg, David A, Wallace, Daniel J, Ramos-Casals, Manuel, Fessler, Barri J, Merrill, Joan T, Dooley, Mary Anne, Khamashta, Munther A, Lunt, Mark, Bernatsky, Sasha, Ramsey-Goldman, Rosalind, Steinsson, Kristjan, Hanly, John G, Gladman, Dafna D, Aranow, Cynthia, Romero-Diaz, Juanita, Mackay, Meggan, Bae, Sang-Cheol, Zoma, Asad A, Nived, Ola |
| Jazyk: |
angličtina |
| Rok vydání: |
2015 |
| DOI: |
10.17615/3782-9v26 |
| Popis: |
BackgroundThe metabolic syndrome (MetS) may contribute to the increased cardiovascular risk in systemic lupus erythematosus (SLE). We examined the association between MetS and disease activity, disease phenotype and corticosteroid exposure over time in patients with SLE.MethodsRecently diagnosed (1, higher disease activity, increasing age and Hispanic or Black African race/ethnicity were independently associated with MetS over the first 2 years of follow-up in the cohort.ConclusionsMetS is a persistent phenotype in a significant proportion of patients with SLE. Renal lupus, active inflammatory disease and damage are SLE-related factors that drive MetS development while antimalarial agents appear to be protective from early in the disease course. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
